Search

Recent advancements in head-mounted wearable technology are revolutionizing the field of biopotential measurement, but the integration of these technologies into practical, user-friendly devices remains challenging due to issues with design intrusiveness, comfort, reliability, and data privacy. To address these challenges, this paper presents GAPSES, a novel smart glasses platform designed for unobtrusive, comfortable, and secure acquisition and processing of electroencephalography (EEG) and electrooculography (EOG) signals.We introduce a direct electrode-electronics interface within a sleek frame design, with custom fully dry soft electrodes to enhance comfort for long wear. The fully assembled glasses, including electronics, weigh 40 g and have a compact size of 160 mm × 145 mm. An integrated parallel ultra-low-power RISC-V processor (GAP9, Greenwaves Technologies) processes data at the edge, thereby eliminating the need for continuous data streaming through a wireless link, enhancing privacy, and increasing system reliability in adverse channel conditions. We demonstrate the broad applicability of the designed prototype through validation in a number of EEG-based interaction tasks, including alpha waves, steady-state visual evoked potential analysis, and motor movement classification. Furthermore, we demonstrate an EEG-based biometric subject recognition task, where we reach a sensitivity and specificity of 98.87% and 99.86% respectively, with only 8 EEG channels and an energy consumption per inference on the edge as low as 121 μJ. Moreover, in an EOG-based eye movement classification task, we reach an accuracy of 96.68% on 11 classes, resulting in an information transfer rate of 94.78 bit/min, which can be further increased to 161.43 bit/min by reducing the accuracy to 81.43%. The deployed implementation has an energy consumption of 40 μJ per inference and a total system power of only 12.4 mW, of which only 1.61% is used for classification, allowing for continuous operation of more than 22 h with a small 75 mAh battery.

Mycophenolate mofetil (MMF) is an inhibitor of inosine monophosphate dehydrogenase, which affects de novo purine synthesis and T- and B-cell proliferation. So far its efficacy and safety as an immunosuppressive treatment have been proven in organ transplantations and also in various autoimmune diseases. A literature search was conducted by using PubMed and the Cochrane library. This review focuses primarily on current treatment with MMF for systemic lupus erythematosus, systemic sclerosis, vasculitis and idiopathic inflammatory myopathies.

The study documents a general change of position on osteoporosis (definition, diagnosis, aim of treatment). Taking into consideration a multifactorial nature of bone fragility in osteoporosis we do not diagnose "osteoporosis" but a total, individual 10-year fracture risk (AR-10) on the basis of independent and self-sufficient risk factors. These are: advanced age, prior fragility fracture, parental history of proximal femur fracture, low BMI, low bone mass, glicocortycosteroids treatment, rheumatoid arthritis, smoking, overuse of alcohol. The treatment should be implemented in persons burdened with a fracture risk higher than a population risk. The intervention threshold is a result of an agreement and a result of work of various working groups of experts. According to Johnell AR-10 below 8% does not require a therapeutical intervention; above 14% justifies the treatment independently of BMD measurement. AR-10 between 8% and 14% is an indication for BMD measurement precising fracture risk. The aim of the treatment is to decrease fracture risk. It combines a limitation of fracture risk factors effects including fall prevention and improvement of bone quality with applying pharmacotherapy. This study highlights that a bone mineral measurement, so far accepted as a criteria for diagnosis of osteoporosis or its exclusion should not be made in aim of diagnosis but to evaluate an absolute fracture risk. Spinal X-rays are performed in aim to diagnose vertebral fractures, which mean a multiple increase of risk of further fractures. The principles of low bone mass differential diagnosis and current possibility of pharmacological treatment are also described. Guidelines for fall avoidance in fracture prevention are described.

This article presents the problem of spinal fractures and the application of vertebro- and kyphoplasty in their treatment. The techniques, outcomes, and complications involved in these procedures are described on the basis of current literature. The advantages and disadvantages of vertebro- and kyphoplasty are discussed.